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SUMMARY
“The dose makes the poison”, the common motto 
of toxicology first expressed by Paracelsus more than 
400 years ago, may effectively serve to guide potential 
applications for metformin and related biguanides in 
oncology. While Paracelsus’ law for the dose-response 
effect has been commonly exploited for the use of some 
anti-cancer drugs at lower doses in non-neoplastic diseases 
(e.g., methotrexate), the opposite scenario also holds true; 
in other words, higher doses of non-oncology drugs, 
such as anti-diabetic biguanides, might exert direct anti-
neoplastic effects. Here, we propose that, as for any drug, 
there is a dose range for biguanides that is without any 
effect, one corresponding to “diabetobiguanides” with a 
pharmacological effect (e.g., insulin sensitization in type 2 
diabetes, prevention of insulin-dependent carcinogenesis, 
indirect inhibition of insulin and growth factor-dependent 
cancer growth) but with minimal toxicity and another 
corresponding to “oncobiguanides” with pharmacological 
(i.e., direct and strong anticancer activity against 
cancer cells) as well as toxic effects. Considering that 
biguanides demonstrate a better safety profile than most 
oncology drugs in current use, we should contemplate 
the possibility of administering biguanides through 
non-conventional routes (e.g., inhaled for carcinomas 
of the lung, topical for skin cancers, intravenous as an 
adjunctive therapy, rectal suppositories for rectal cancer) 
to unambiguously investigate the therapeutic value of 
high-dose transient biguanide exposure in cancer. Perhaps 
then, the oncobiguanides, as we call them here, could be 
viewed as a mechanistically different type of anti-cancer 
drugs employed at doses notably higher than those used 
chronically when functioning as diabetobiguanides.
The antimetabolite drug methotrexate (MTX) was 
originally developed as an anti-cancer agent and, as such, 
received U.S. Food and Drug Administration (FDA) 
approval in 1953. Not long afterwards, MTX was found 
to exert symptomatic control of severe, recalcitrant, 
disabling psoriasis; the FDA officially approved MTX as a 
treatment for psoriasis in the early 1970’s. Today, MTX is 
a well-known chemotherapeutic and immunosuppressive 
agent that is widely and successfully used in many 
rheumatologic, dermatologic, and hematologic diseases 
[1]. Notably, the clinical use of MTX represents a 
paradigmatic example of Paracelsus’ law, which states 
“sola dosis facit venenum (only dose makes the poison)”, 
meaning that the right dose differentiates a poison from 
a remedy; hence, a molecule becomes a drug if the dose 
required to treat a complication is pharmacologically 
active with minimal toxicity. The so-called Paracelsus’ 
“dose-response effect” establishes that, for any drug, 
there is a dose range (concentration) that is without any 
effect, one with a pharmacological effect but minimal 
toxicity (or an acceptable safety profile), and another with 
pharmacological and toxic effects. In the case of MTX, 
experience in multiple sclerosis indicates that the low dose 
of 7.5 mg per square meter (m2) per week (0.1 mg kg-
1) for up to 2 years is not associated with toxicity. The 
use of doses of MTX up to 30 mg per week (0.4 mg kg-1) 
in the treatment of juvenile and rheumatoid arthritis and 
psoriasis is associated with an acceptable toxicity profile. 
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Drastically higher doses of MTX, up to 5,000-12,000 mg 
per m2 (130-300 mg kg-1) for several weeks, a dosage that 
can yield serum concentrations of >1,000 µmol/L (i.e., 
within the range of concentrations associated with life-
threatening MTX toxicity), are used for the treatment of 
cancer. MTX is therefore used as an “onco drug” at doses 
up to 1,000-fold higher than those employed chronically 
for separate indications in immune diseases such as 
rheumatoid arthritis and multiple sclerosis. 
During the early 1970’s with the cancer-to-psoriasis 
drug repositioning of MTX, Canada approved the use 
of metformin, a member of the biguanide class of drugs 
that also includes the withdrawn agents phenformin and 
buformin, for the treatment of type 2 diabetes. Metformin 
is now one of the most prescribed drugs worldwide; in 
2010, there were more than 100 million prescriptions 
worldwide for metformin, alone and in combination. 
Starting in 2005 with a report by Evans et al. entitled 
“Metformin and reduced risk of cancer in diabetic 
patients” [2], numerous epidemiological and case-
controlled studies have repeatedly suggested that the use 
of metformin in diabetic patients appears to be associated 
with a significantly lower risk of cancer mortality 
and incidence in comparison to other anti-diabetic 
medications. Since then, the hypothesis that metformin 
may have clinically relevant preventive and treatment 
effects against human cancers has exploded as an ever-
growing research field, as scientists have discovered 
metformin’s multi-faceted anti-cancer mechanisms 
linked to malignization and even to so-called cancer stem 
cells (CSCs) [3-6]. Thus, the molecular and pre-clinical 
breakthroughs in “anti-cancer metformin” have taken 
place in the past decade, and many phase II and II clinical 
trials of metformin are now in progress (as of February 
2014, the clinicaltrials.gov database lists more than 60) 
to examine the effects of metformin on various cancer 
endpoints. 
Although the present, metformin-based clinical 
investigations aim to test the relevant hypothesis that a 
practical, long-term administration of conventional anti-
diabetic doses of this biguanide may have significant 
anticancer activity, most of metformin’s antineoplastic 
mechanisms of action that appear to operate in preclinical 
models [3-6] will remain obscured in these trials, as 
drug exposure in target cancer tissues may be clearly 
suboptimal. In the cancer prevention scenario, where 
side effects are less acceptable than they are in the 
area of cancer treatment, we might only consider the 
hypothesis that the conventional dose for the treatment of 
diabetes, or even lower doses, will be clinically useful. 
In the cancer treatment scenario, however, the assumption 
that the antineoplastic effects of metformin are solely 
attributable to its indirect, endocrine-like effects, such as 
its insulin-lowering effects, which are generally proposed 
to slow tumor growth in hyperinsulinemic patients with 
insulin-addicted cancers, could only explain the currently 
adopted long-term treatment with diabetic doses for 
maximal benefit in cancer patients. Conversely, if we 
assume the real possibility that the antitumoral activity 
of metformin can be attributed to its many direct actions 
on target cancer cells as shown in vitro, we should then 
consider that, in certain contexts, short-term exposure 
to higher doses of biguanides could have clinical use 
in oncology. Thus, in addition to the fact that particular 
tissues known to accumulate relatively high metformin 
levels following conventional oral dosing (e.g., liver, 
gastrointestinal tract) may provide proof-of-concept 
clinical models for investigation of the occurrence and 
relevance of metformin’s direct mechanisms of action 
(e.g., reduction of hepatoma risk, prevention of familial or 
sporadic intestinal polyposis) [7], we should contemplate 
the utility of other unconventional routes of short-term 
high-dose metformin exposure alone and in combination 
regimens. As for the above-mentioned case of MTX, we 
here propose that “oncobiguanides” should be viewed as 
a different type of anti-cancer drugs when employed at 
doses notably higher than those used chronically when 
operating as “diabetobiguanides”. 
The notion that conventional phase I and II trials 
must explore the possibility of exposing tumors to the 
higher biguanide concentrations used in many preclinical 
models is certainly supported by the strong anti-cancer 
efficacy of the intraperitoneal high-dose exposure to 
metformin observed in PI3K-mutated, insulin-independent 
human cancer xenotumors, in which the anti-cancer 
effects of metformin necessarily involve mechanisms 
distinct from those that might operate with the doses used 
in the clinical management of type 2 diabetes [8]. In our 
hands, ad libitum access to water containing oral 250 mg 
kg-1 metformin beginning 1 week prior to inoculation 
of MCF10DCIS.com breast cancer cells harboring 
the insulin-unresponsive PIK3CA-activating mutation 
H1047R modestly affected the growth of the xenotumors, 
reaching a maximum of 43% at 4 weeks after cell 
inoculation and decreasing toward the end of the treatment 
(approximately 30-35%). Moreover, oral metformin did 
not affect tumor incidence, the proliferation factor mitotic 
activity index (MAI), or the anatomopathological features 
of MCF10DCIS.com cancer tissues. To determine if oral 
metformin produced plasmatic levels of metformin that 
could be comparable to those achieved in humans, we 
recently assessed plasma concentrations of metformin 
at the end of the 8-week treatment using HPLC coupled 
to ESI-QTOF-MS. Mice that were treated with an oral 
dosing schedule achieved a concentration of 4.7 ± 1.3 
µmol/L (~0.6 µg/mL) metformin, which is consistent with 
the steady-state values that have been reported in diabetic 
patients at the usual clinical doses and schedules. We then 
measured the circulating insulin level following exposure 
to oral metformin (even though this is not a diabetic 
model) and found that oral metformin significantly 
decreased insulin levels by ~35%. Although it could be 
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hypothesized that a modest but prolonged suppression of 
insulin signaling by oral metformin at conventional, anti-
diabetic doses can be sufficient to inhibit the growth of 
breast xenotumors, a role for insulin can be eliminated in 
PIK3CA H1047R-mutated MC10DCIS.com cells, which 
have been shown to proliferate regardless of the presence 
or absence of insulin in vitro and to form tumors that are 
refractory to dietary restriction (DR) in vivo. Therefore, 
the metformin-induced inhibition of additional signaling 
pathways, e.g., the liver-derived production of circulating 
growth factors that ultimately activate local oncogenic 
signaling in cancer tissues [9] as well as bioenergetic and 
anabolic machinery in cancer cells, may be involved. 
We hypothesized that a different route of 
administration of metformin, such as intraperitoneal (i.p.) 
injection, could be more effective because the peak plasma 
concentrations would be higher than those that could be 
achieved with oral metformin. Accordingly, insulin-
independent, DR-refractory MCF10DCIS.com xenotumors 
were exquisitely sensitive to the daily, i.p. administration 
of 200 mg kg-1 metformin beginning 1 week before the 
inoculation of cancer cells. The anti-cancer activity of 
daily i.p. metformin increased in a time-dependent manner 
and reached a highly significant >80% inhibition of tumor 
growth by the end of the 8-week treatment. Moreover, 
treatment with metformin using the i.p. administration 
route significantly reduced the proliferation factor MAI 
by ~50% and notably decreased the tumor cellularity in 
MCF10DCIS.com cancer tissues [8]. Notably, HPLC-
ESI-QTOF-MS pharmacokinetic analysis showed that the 
Figure 1: Dose–response anti-cancer effect of biguanides in humans, as per Paracelsus’ law. Top panel. As for any drug, 
there is a dose range for biguanides that is without any anti-cancer effect, one corresponding to “diabetobiguanides” with a pharmacological 
effect (e.g., insulin sensitization in type 2 diabetes, prevention of insulin-dependent carcinogenesis, indirect inhibition of insulin- and 
growth factor-dependent cancer growth) but with minimal toxicity and another corresponding to “oncobiguanides” with pharmacological 
(i.e., direct and strong activity against cancer cells including CSCs) as well as toxic effects. Bottom panel. Because biguanides demonstrate 
a better safety profile than most oncology drugs in current use, we should contemplate the possibility of administering biguanides through 
non-conventional routes (e.g., inhaled for carcinomas of the lung, topical for skin cancers, intravenous combination chemotherapy, rectal 
suppositories for rectal cancer) to unambiguously investigate the therapeutic value of high-dose transient biguanide exposure in cancer. The 
original painting in the top panel is from Dr. Jorge Joven.
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plasma levels of metformin immediately after the last i.p. 
injection were ~150-fold higher than those obtained with 
the oral dosing schedule. Thus, mice that were treated 
with the i.p. dosing schedule achieved 679 ± 16 µmol/L 
(~87 µg/mL) metformin, a circulating dose of metformin 
that is within the lower limit observed in an individual 
with metformin poisoning but that was surprisingly well 
tolerated and did not significantly affect either the general 
health or the weight of the mice throughout the course of 
the study. Strikingly, the highly efficacious and extremely 
high circulating concentrations of metformin achieved 
following i.p. administration failed to decrease insulin 
levels to the extent observed with the oral metformin-
dosing schedule. 
Blood or plasma concentrations of metformin are 
typically in the range of 7.8-31.2 µmol/L (1-4 µg/mL) 
in diabetic persons receiving the drug therapeutically; 
indeed, during controlled clinical trials, the maximum 
plasma levels did not generally exceed 39 µmol/L 
(5 µg/mL) metformin, even at maximum doses. 
Circulating concentrations of 312-836 µmol/L (40-120 
µg/mL) can be detected in victims of acute metformin 
overdose, and concentrations of 624-1,560 µmol/L 
(80-200 µg/L) are seen in metformin fatalities. Yet, the 
“unsafe” concentration of metformin is not precisely 
known. Moreover, the actual relevance of measuring 
the circulating levels of metformin in predicting the 
risk of lactic acidosis remains unclear. Additionally, 
although there is uncertainty concerning the feasibility of 
administering biguanides through non-conventional routes 
to investigate the therapeutic value of high-dose transient 
exposure, we should acknowledge that biguanides have a 
better safety profile than most oncology drugs in current 
use [7]. Perhaps it is time to consider that, as with any 
drug, there is a metformin dose range that is without any 
effect, one corresponding to “diabetobiguanides” with a 
pharmacological effect (e.g., insulin sensitization in type 2 
diabetes, prevention of insulin-dependent carcinogenesis, 
indirect inhibition of insulin- and growth factor-dependent 
cancer growth) but with minimal toxicity and another 
corresponding to “oncobiguanides” with pharmacological 
(i.e., direct and strong anti-cancer activity) as well as toxic 
effects (Fig. 1, top). 
As stated by Paracelsus more than 400 years ago, 
it is “the dose that makes a drug”; this principle has been 
exploited for the use of some anti-cancer drugs at lower 
doses in several non-neoplastic diseases. As the opposite 
scenario also holds true, i.e., higher doses of non-oncology 
drugs (such as the anti-diabetic biguanides) exerting anti-
neoplastic effects, the exploitation of available biguanides 
(metformin, phenformin, buformin) or libraries of novel 
biguanides using nonconventional routes of administration 
(e.g., inhaled, topical, parental, rectal, etc) to achieve 
short-term high-dose exposure in cancer tissues (Fig. 
1, bottom) could represent a cost-effective and efficient 
channel to optimize pharmacokinetics and develop 
rational combinations in a forthcoming second-generation 
of biguanide-based trials in oncology. While endless 
pharmacovigilance has monitored the safety profile of 
the diabetobiguanide metformin, its natural ancestor, 
guanidine-rich Galega officinalis (known as “Professor-
Weed” in the USA), is a Class A Federal Noxious Weed in 
35 states of the United States and appears on the database 
of poisonous plants [10], ironically recapitulating the 
dose-response effect of metformin in humans, as per 
Paracelsus’ law.
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